Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget - United States
doi 10.18632/oncotarget.4076
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

A Case of Hepatocellular Carcinoma With Pulmonary Metastasis Who Showed Complete Response by Cytotoxic Chemotherapy After Sorafenib Failure

Journal of Liver Cancer
2017English

A Complete Response Induced by 21-Day Sorafenib Therapy in a Patient With Advanced Hepatocellular Carcinoma

Internal Medicine
Internal MedicineMedicine
2013English

Retrospective Analysis of Transarterial Chemoembolization and Sorafenib in Chinese Patients With Unresectable and Recurrent Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs
OncologyPharmacology
2011English

Early Α-Fetoprotein Response Predicts Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

Journal of Hepatocellular Carcinoma
2015English

Overall Survival in Response to Sorafenib Versus Radiotherapy in Unresectable Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis: Propensity Score Analysis

BMC Gastroenterology
MedicineGastroenterology
2014English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy